St. Louis Financial Planners Asset Management LLC Takes $5.01 Million Position in AbbVie Inc. $ABBV

St. Louis Financial Planners Asset Management LLC acquired a new position in AbbVie Inc. (NYSE:ABBV) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 19,202 shares of the company’s stock, valued at approximately $5,013,000. AbbVie accounts for approximately 2.6% of St. Louis Financial Planners Asset Management LLC’s portfolio, making the stock its 7th largest holding.

Other hedge funds also recently bought and sold shares of the company. Norges Bank purchased a new position in AbbVie in the fourth quarter worth about $5,865,055,000. Wellington Management Group LLP lifted its stake in shares of AbbVie by 457.4% in the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Capital World Investors lifted its stake in shares of AbbVie by 106.3% in the 4th quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after purchasing an additional 6,736,161 shares during the period. Cardano Risk Management B.V. boosted its holdings in shares of AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock worth $1,244,112,000 after buying an additional 4,908,260 shares during the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after buying an additional 4,190,487 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.0%

AbbVie stock opened at $243.64 on Friday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market capitalization of $430.46 billion, a price-to-earnings ratio of 68.82, a P/E/G ratio of 0.82 and a beta of 0.30. The firm has a 50 day moving average of $241.40 and a 200 day moving average of $224.82.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts predict that AbbVie Inc. will post 14.06 EPS for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. AbbVie’s payout ratio is 195.48%.

Analyst Ratings Changes

A number of brokerages have commented on ABBV. Citigroup upped their target price on shares of AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Erste Group Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday. Cantor Fitzgerald boosted their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an “overweight” rating in a research report on Monday. Barclays upped their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Finally, UBS Group raised their target price on AbbVie from $230.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $275.70.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie delivered a robust second quarter, with earnings and revenue exceeding analyst expectations. Revenue increased approximately 10% year over year, while management raised its revenue outlook and cited continued momentum from key products. ABBV Stock Dips 4% Despite Robust Q2
• Positive Sentiment: Analyst sentiment remains favorable. Erste Group Bank upgraded AbbVie from “hold” to “buy,” and Cantor Fitzgerald raised its price target to $285, suggesting potential upside from current levels. Cantor Fitzgerald Boosts AbbVie Price Target
• Positive Sentiment: AbbVie’s long-running dividend-growth record continues to support its appeal to income-focused investors, providing a potential floor for the stock despite valuation and acquisition concerns. This Stock Keeps Raising Its Dividend
• Neutral Sentiment: The Apogee acquisition is intended to expand AbbVie’s growth pipeline, but investors are assessing whether the strategic benefits will justify the transaction’s cost and integration risks. Baron Capital Exits Apogee Therapeutics
• Negative Sentiment: AbbVie reduced its 2026 adjusted EPS outlook to reflect the Apogee deal, offsetting the positive quarterly results and higher revenue guidance. The lower earnings forecast appears to be the main catalyst behind the stock’s decline. ABBV Stock Dips 4% Despite Robust Q2
• Negative Sentiment: AbbVie priced approximately $9.9 billion of senior notes to help fund the acquisition. The financing increases debt obligations and may intensify concerns about leverage, interest expense, and near-term shareholder returns. AbbVie Prices Senior Notes to Fund Acquisition

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.